Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Taps CMM to Help Develop Women's Health Biomarkers

NEW YORK (GenomeWeb News) – Qiagen will use a database and software, as well as clinical samples, from the Center for Molecular Medicine in research aimed at developing biomarkers for breast cancer and other women’s health issues, the company said today.
 
The agreement gives Qiagen access to CMM’s XenoBase software and database, which was developed by CMM’s partner, the Van Andel Research Institute, to “identify clinically actionable associations between diseases, biomarkers and treatments,” the company said. 
 
After the initial biomarker research is completed, Qiagen also may use CMM’s genomics and proteomics laboratory services to develop and validate molecular diagnostic tests.
 
Financial terms of the agreement were not released.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.